Nexalin Technology Commits $945K to Advance Pivotal HALO™ Clarity Insomnia Trial

summarizeSummary

Nexalin Technology has entered into a material agreement with Lindus Health, committing approximately $945,000 to conduct a pivotal clinical trial for its HALO™ Clarity device, targeting FDA De Novo Classification for moderate-to-severe insomnia.

check_boxKey Events

• Secures CRO for Pivotal Trial

  Nexalin Technology entered into a Scope of Work with Lindus Health Limited, a clinical research organization, to conduct the pivotal clinical trial for its HALO™ Clarity device for moderate-to-severe insomnia.

• Significant Financial Commitment

  The company will pay Lindus Health approximately $944,820 in direct fees, plus pass-through expenses, structured on a milestone basis. This represents a substantial investment for the company.

• Advancing FDA De Novo Strategy

  The 160-participant, triple-blinded, sham-controlled study is designed to support Nexalin's planned De Novo Classification Request to the U.S. FDA, aiming to establish the HALO™ Clarity as a new product category.

• Enrollment Expected Q2 2026

  Patient enrollment for the pivotal clinical trial is currently expected to begin in the second quarter of 2026, marking a key milestone in the company's regulatory program.

auto_awesomeAnalysis

This filing details a critical agreement for Nexalin Technology, a company facing a going concern warning, to advance its pivotal clinical trial for the HALO™ Clarity device. The commitment of nearly $945,000 to Lindus Health, a clinical research organization, represents a substantial investment relative to the company's market capitalization. This move is a significant step in the company's FDA strategy, aiming for a De Novo Classification Request, and is essential for its long-term viability and potential commercialization of its core product. Investors should monitor the progress of this trial as it is crucial for the company's future.